This study is for people with advanced kidney cancer (renal cell carcinoma). It's testing different combinations of medicines: fianlimab, cemiplimab, ipilimumab, and nivolumab. You would be randomly assigned to one of three groups. Two groups will receive fianlimab and cemiplimab, with one of those groups also receiving ipilimumab. The third group will receive the standard treatment of ipilimumab and nivolumab. The main goal is to see how many people respond to the treatments after two years. To join, you need to be at least 18 years old and have a good performance status, meaning you can do most daily activities. The study is currently unclear about its recruitment status and plans to enroll 120 participants.

Study design

This is a randomized Phase 2 study with three groups, enrolling 120 participants. You would be randomly assigned to one of the treatment groups.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The main goal of the study is measured at 2 years, which suggests follow-up for at least that long.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.